The pathophysiology of the haemostatic mechanism is central to both haemorrhagic disease and thrombosis, and rational therapy of such diseases must be based on understanding it. Blood loss after injury is minimized by a complex series of interrelated reactions involving vascular constriction, the production of a platelet plug, and the formation of fibrin through the coagulation mechanism. Probably vasoconstriction, a transient reaction, is of relatively minor importance.
The pathophysiology of the haemostatic mechanism is central to both haemorrhagic disease and thrombosis, and rational therapy of such diseases must be based on understanding it. Blood loss after injury is minimized by a complex series of interrelated reactions involving vascular constriction, the production of a platelet plug, and the formation of fibrin through the coagulation mechanism. Probably vasoconstriction, a transient reaction, is of relatively minor importance.
Platelet Function
The contribution of platelets to haemostasis is paramount, particularly after damage to small blood vessels. At the site of endothelial damage platelets adhere to the vessel wall; this may be initiated by exposed collagen or adenosine diphosphate (ADP) released from damaged tissue. In vitro experiments have shown that this initial adhesion of platelets results in the release of ADP from the platelets, which induces aggregation of further platelets and the release reaction in which ADP, a phospholipid (platelet factor 3) required for the coagulation mechanism, 5-hydroxytryptamine, and other substances are released from platelets. The functional result of this initial reaction is the formation of a plug of aggregated platelets to seal the breech in the vessel wall. At this stage aggregation is reversible, but thrombin formed via the coagulation mechanism produces structural changes in the platelets and irreversibility of aggregation.
Platelet adhesion and aggregation are affected by several drugs. Aspirin inhibits the platelet release reaction and thereby blocks platelet aggregation, and several other drugs, including dipyridamole and its derivatives, inhibit ADP-induced platelet aggregation. Dextrans also interfere with platelet function, reducing platelet adhesiveness and diminishing platelet aggregation and the release of platelet factor 3.
Coagulation Mechanism
The platelet plug is reinforced or enlarged by the formation of fibrin resulting from the conversion of soluble fibrinogen by thrombin. Thrombin is formed from its circulating precursor prothrombin through two principal pathways, known as the intrinsic and extrinsic coagulation mechanisms. Both pathways are believed to be a series of reactions in which an enzyme precursor is converted to its active form in sequence, the activated form then converting the next enzyme precursor to its active state. The precise sequence of reactions is not finally established: a schematic representation of a current view is shown in the figure.
INTRINSIC PATHWAY
The intrinsic pathway begins with the activation of factor XII. This factor is activated in the laboratory by contact with glass or other negatively charged agents; physiological activators of factor XII include collagen and skin, and, in addition to its effect on platelets, possibly exposed collagen plays a part on the haemostatic process by initiating clotting. People deficient in factor XII have no recognizable disability and do not suffer from a haemorrhagic tendency-indicating that alternative mechanisms for the initiation of coagulation must exist. The recent finding that collagen can induce coagulant activity in platelets with initiation of intrinsic coagulation, bypassing factor XII activation, may explain the absence of bleeding in factor XII-deficient people.
Activated factor XII converts factor XI to its active form: in turn, activated factor XI has a role in activating factor IX (Christmas factor), which takes part with factor VIII (antihaemophilic globulin) in converting factor X to its activated form. In the presence of factor V and phospholipid activated factor X converts prothrombin to thrombin. The procoagulant activities of both factor VIII and factor V are greatly enhanced by the presence of thrombin, and ionic calcium is required for several of the reactions in the coagulation sequence.
Factor VIII is of particular clinical importance, being the material deficient in patients with classical haemophilia, the commonest hereditary bleeding disorder. Recently it has been recognized that a protein antigenically identical (as detected by heterologous antiserum) to normal factor VIII protein is present in patients with haemophilia, but is functionally inert. Factor VIII clot-promoting activity is also reduced in patients with von Willebrand's disease, but in this disorder the concentration of the factor VIII-like antigenic material is also reduced. The clot-promoting activity of factor VIII is heat-labile and rapidly disappears from blood or plasma on storage: fresh frozen plasma stored at -70°C, however, retains its activity for several months and factor VIII may be prepared in concentrated form in cryoprecipitates of fresh normal plasma.
BRITISH MEDICAL JOURNAL 28 SEPTEMBER 1974 The core of the fibrinolytic enzyme system is the conversion of plasminogen to the protease plasmin (see fig.) This is achieved physiologically by activators derived from the vascular wall, and, possibly, by a pathway initiated by the activation of factor XII. Several agents provoke an increased level of circulating plasminogen activator. Intravenous nicotinic acid produces intense but transient fibrinolytic activity, but resistance develops after repeated doses. Most study has been given to the combination of anabolic steroids with an oral diguanide which produces a sustained enhancement of plasma fibrinolytic activity. The mechanism of action is unproved, but during such therapy the activator content of the walls of superficial veins increases. The extrinsic pathway consists of factors VII, V, X, and tissue thromboplastin-which react to form an agent capable of converting prothrombin to thrombin. The vitamin Kdependent clotting factors are prothrombin, VII, IX, and X; they are synthesized in the liver and their formation is blocked by the coumarin and indanedione anticoagulant drugs.
Thrombin splits fibrinopeptides from fibrinogen molecules with the formation of fibrin monomer-which, in the presence of calcium, produces a friable clot soluble in such solvents as 5 M urea and 1% monochloroacetic acid. Finally-in the presence of a plasma transglutaminase (factor XIII; fibrin stabilizing factor), thrombin, and calcium-the fibrin polymer is stabilized by the formation of inter-chain peptide bonds resulting in an insoluble clot, which is haemostatically efficient.
Naturally occurring inhibitors of the coagulation mechanism probably play some part in physiological haemostasis. Heparin with a cofactor, an a2-globulin now known as antithrombin III, inhibits thrombin and thereby interferes with the formation of fibrin and with the potentiation of the procoagulant activities of factors V and VIII by thrombin. Heparin may also increase the activity of antithrombin III, which is the natural inhibitor of activated factor X: this effect provides the rationale for the use of low-dosage heparin in the prophylaxis of thrombosis.
Several snake venoms affect the coagulation mechanism. A purified fraction of the venom of the Malayan pit viper (Agkistrodon rhodostoma) known as ancrod converts fibrinogen into an unstable fibrin. After administration in vivo, the plasma fibrinogen is depleted, with consequent anticoagulation. The fibrin formed is removed by the action of the fibrinolytic enzyme system.
Fibrinolytic Enzyme System
The precise physiological function of the fibrinolytic system has not been established, but it is postulated that its action limits the persistence of unwanted fibrin. Interest in this system has been fostered by the possibility of harnessing its potential power to dissolve pathological fibrin deposits, and using agents which inhibit fibrinolytic activity for the management of haemorrhagic disorders. Haemorrhagic Disease A haemorrhagic tendency may result from an abnormality of any of the three major components of the haemostatic mechanism. Severe bleeding from vascular defects-congenital (for example, hereditary haemorrhagic telangiectasia) or acquired (for example, scurvy)-may occur, and bleeding from platelet disorders is both common and potentially life-threatening. Thrombocytopenia, due to a failure of platelet production or a reduction in platelet survival, is the commonest type of platelet abnormality causing a bleeding disorder, but hereditary disorders of platelet function such as thrombosthenia or the giant platelet syndrome are recognized causes of a bleeding tendency.
Deficiency of clotting factors, resulting in impairment of haemostasis, tends to produce delayed but persistent bleeding after injury. Acquired deficiencies-due, for example, to liver disease, vitamin K deficiency, the administration of coumarin anticoagulants, or consumption coagulopathy-are usually multiple, whereas hereditary deficiencies are almost invariably single.
Disseminated Intravascular Coagulation
Several stimuli can induce widespread intravascular thrombosis with resultant consumption of fibrinogen, platelets, and clotting factors (consumption coagulopathy). These stimuli include the entry into the circulation of coagulant agents such as placental material during obstetric complications, and damage to the vascular endothelium as a result of inflammation or allergy. Such a process may be acute, with the production of a severe haemorrhagic state, or exist in a subacute or chronic form, with mild purpura or no bleeding features. The intravascular presence of fibrin normally stimulates the secondary development of local fibrinolytic activity but may, occasionally, be accompanied by an increase in systemic fibrinolytic activity.
Hyperplasminaemia Primary hyperplasminaemia is due to the rapid formation of plasmin in excess of the ability of the circulating antiplasmins to neutralize it, resulting in proteolysis of fibrinogen and coagulation factors. Doctors may cause this during thrombolytic therapy, but otherwise hyperplasminaemia is rare, but it may occur in patients with prostatic carcinoma and metastases, cirrhosis of the liver, and after major thoracic operations. Thrombosis Intravascular thrombosis probably requires the participation of platelets and activation of the coagulation mechanism. It is also well known that the structure of arterial and venous thrombi differ: arterial thrombi consist principally of a platelet mass at a site of definite vascular injury whereas the venous thrombus has a small platelet head and a large tail of fibrin and red cells. The importance of the large fibrin tail of thrombi in the major veins lies in the ease -with which it may be detached with resultant pulmonary embolism, but in arterial thrombi the initial platelet aggregates are loose and may also be detached and carried onward in the blood stream. In the case of thrombosis in the carotid artery, such platelet aggregates may occasionally be seen in the retinal vessels and produce transient visual disturbances (amaurosis fugax).
The precise mechanisms triggering arterial and venous thrombosis are uncertain and discussion on hypotheses are outside the scope of this article. In the case of arterial thrombi related to plaques of atheroma presumably platelets adhere to the damaged wall and initiate thrombosis, but it is not known whether venous thrombosis starts with the formation of a small platelet nidus or whether the activation of the coagulation mechanism with fibrin formation is independent of platelet adhesion and aggregation. One suggestion is that venous thrombi may commence with the formation of platelet thrombi in valve cusps, but as no histological differences can be found in the endothelium of valve pockets with and without thrombi the factor responsible for initiating thrombosis remains speculative. The origins of this occasion, and of their interest in it, are told elsewhere.' Beginning as "The Medical Society for the Care of the Elderly," the change to our present title was made 15 years ago though the founders chose theirs with care to exclude "geriatrics," a word some consider ugly and unscholarly.' As an alternative "Eld Heath" has been suggested to me by Professor John Braidwood of the English Language department at Queen's University because "Child Health" is more felicitous than "paediatrics," and the early English equivalent of "child" for an old ager was "eld".
Objectives
The pioneers had four main objectives: Classification-defining simple categories of disease and disability to resolve the anarchy of chronic hospitals and allocate care according to need.
